Claims for Patent: 5,221,763

Summary for Patent: 5,221,763

Title:	Prostaglandins of the F series
Abstract:	The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.
Inventor(s):	Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Oda; Tomio (Itami, JP)
Assignee:	R-Tech Ueno, Ltd. (Osaka, JP)
Application Number:	07/945,594
Patent Claims:	1. A 13,14-dihydro-15-keto-PGF represented by the formula: in which a bond between C-2 and C-3 is a single or a double bond, X is a group: ##STR37## R.sub.1 is a hydrogen atom or a C.sub.1-4 alkyl, phenyl, benzoyl, hydroxyalkyl, alkoxyalkyl, trialkylsilyl or tetrahydropyranyl group; R.sub.2 is a hydrogen atom or a lower alkyl group; R.sub.3 is hydroxyl; R.sub.3 is hydroxyl; R.sub.4 and R.sub.5 are the same or different, and signify a hydrogen atom, a halogen atom, or a lower alkyl group; and when at least one of R.sub.4 and R.sub.5 is a halogen atom, R.sub.6 is a C.sub.4-9 alkyl group which may be branched or contain a double bond, a C.sub.1-9 alkyl group containing a C.sub.1-2 alkoxy substituent or ##STR38## (wherein R.sub.7 is a hydrogen or halogen atom or a halogenated methyl group); or when R.sub.4 and R.sub.5 are independently a hydrogen atom or a lower alkyl group, R.sub.6 is a C.sub.6-9 alkyl group which may be branched or contain a double bond, a C.sub.1-9 alkyl group containing a C.sub.1-2 alkoxy substituent or ##STR39## (wherein R.sub.7 is as above defined); and a physiologically acceptable salt of said 13,14-dihydro-15-keto-PGF. 2. 13,14-dihydro-15-keto-PGFs according to claim 1, wherein R.sub.1 is an alkyl group h aving a carbon number of one to four. 3. 13,14-dihydro-15-keto-PGFs and physiologically acceptable salts thereof according to claim 1, wherein at least one of R.sub.4 and R.sub.5 is a halogen atom. 4. 13,14-dihydro-15-keto-PGFs and physiologically acceptable salts thereof according to claim 1, wherein at least one of R.sub.4 and R.sub.5 is a lower alkyl group. 5. 13,14-dihydro-15-keto-PGFs and physiologically acceptable salts thereof according to claim 1, wherein each of R.sub.4 and R.sub.5 is a lower alkyl group. 6. 13,14-dihydro-15-keto-PGFs and physiologically acceptable salts thereof according to claim 1, wherein each of R.sub.4 and R.sub.5 is a halogen atom. 7. 13,14-dihydro-15-keto-PGFs and physiologically acceptable salts thereof according to claim 1, being 13,14-dihydro-15-keto-16-desbutyl-16-trifluoromethyl-phenxoy-PGFs. 8. 13, 14-dihydro-15-keto-PGFs and physiologically acceptable salts thereof according to claim 1 being a 13,14-dihydro-15-keto-16, R,S-fluoro-PGF.sub.2.alpha. -methyl ester. 9. A 13,14-dihydro-15-keto-PGF of claim 1 being a 13,14-dihydro-15-keto-20-ethyl-PGF represented by the formula: ##STR40## or a physiologically acceptable salt thereof. 10. A 13,14-dihydro-15-keto-PGF of claim 1 being a 13,14-dihydro-15-keto-16-substituted-PGF represented by the formula: ##STR41## wherein at least one of R.sub.4 and R.sub.5 is a halogen atom; or a physiologically acceptable salt thereof. 11. A 13,14-dihydro-15-keto-PGF of claim 1 being a 13,14-dihydro-15-keto-16-desbutyl-16-phenoxy-PGF represented: by the formula: ##STR42## or a physiologically acceptable salt thereof. 12. A 13,14-dihydro-15-keto-PGF of claim 1 being a 13,14-dihydro-15-keto-20-ethyl-PGF.sub.2.alpha., a C.sub.1 -C.sub.4 alkyl ester or a physiologically acceptable salt thereof. 13. A 13,14-dihydro-15-keto-PGF of claim 1 being a 13,14-dihydro-15-keto-20-ethyl-PGF.sub.2.alpha. isopropyl ester.